Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a report published on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $84.00 price target on the stock.

Several other equities analysts have also recently commented on DFTX. Stifel Nicolaus boosted their price target on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Citigroup reissued a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Canaccord Genuity Group set a $78.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 15th. Wall Street Zen downgraded Definium Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of Definium Therapeutics in a research report on Monday, September 14th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $66.00.

Definium Therapeutics Stock Performance

Shares of NASDAQ DFTX opened at $36.90 on Friday. Definium Therapeutics has a 12 month low of $10.46 and a 12 month high of $49.70. The company has a market cap of $4.96 billion, a price-to-earnings ratio of -10.76 and a beta of 2.19. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The business has a fifty day simple moving average of $40.30 and a 200-day simple moving average of $33.09.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Sell-side analysts predict that Definium Therapeutics will post -3.02 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Robert Barrow sold 31,550 shares of the stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $1,153,783.50. Following the completion of the sale, the chief executive officer directly owned 2,213,090 shares of the company’s stock, valued at approximately $80,932,701.30. This represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of the firm’s stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $123,496.89. Following the completion of the sale, the chief financial officer owned 394,528 shares in the company, valued at approximately $14,427,888.96. The trade was a 0.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 71,098 shares of company stock valued at $2,626,115 over the last ninety days. 2.40% of the stock is owned by insiders.

Institutional Trading of Definium Therapeutics

Hedge funds have recently bought and sold shares of the stock. Nykredit A S acquired a new stake in Definium Therapeutics in the 2nd quarter worth $45,000. GAMMA Investing LLC raised its position in shares of Definium Therapeutics by 28.3% during the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company’s stock valued at $59,000 after buying an additional 343 shares during the last quarter. Allworth Financial LP acquired a new position in shares of Definium Therapeutics during the second quarter valued at about $110,000. Integrated Wealth Concepts LLC acquired a new position in shares of Definium Therapeutics during the second quarter valued at about $159,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Definium Therapeutics in the second quarter valued at about $222,000. 27.91% of the stock is owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.